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Trans-ethnic Fine Mapping Highlights
Kidney-Function Genes Linked to Salt Sensitivity
Anubha Mahajan,1 Aylin R. Rodan,2 Thu H. Le,3 Kyle J. Gaulton,4 Jeffrey Haessler,5 Adrienne M. Stilp,6
Yoichiro Kamatani,7 Gu Zhu,8 Tamar Sofer,6 Sanjana Puri,2 Jeffrey N. Schellinger,2 Pei-Lun Chu,3
Sylvia Cechova,3 Natalie van Zuydam,1 the SUMMIT Consortium, the BioBank Japan Project,
Johan Arnlov,9,10 Michael F. Flessner,11 Vilmantas Giedraitis,12 Andrew C. Heath,13 Michiaki Kubo,14
Anders Larsson,9 Cecilia M. Lindgren,1,15 Pamela A.F. Madden,13 Grant W. Montgomery,16
George J. Papanicolaou,17 Alex P. Reiner,5 Johan Sundstro¨m,9 Timothy A. Thornton,6 Lars Lind,9
Erik Ingelsson,18,19 Jianwen Cai,20 Nicholas G. Martin,8 Charles Kooperberg,5 Koichi Matsuda,21
John B. Whitfield,8 Yukinori Okada,7,22 Cathy C. Laurie,6 Andrew P. Morris,1,23,25,*
and Nora Franceschini24,25,*
We analyzed genome-wide association studies (GWASs), including data from 71,638 individuals from four ancestries, for estimated
glomerular filtration rate (eGFR), a measure of kidney function used to define chronic kidney disease (CKD). We identified 20 loci attain-
ing genome-wide-significant evidence of association (p < 53 108) with kidney function and highlighted that allelic effects on eGFR at
lead SNPs are homogeneous across ancestries. We leveraged differences in the pattern of linkage disequilibrium between diverse popu-
lations to fine-map the 20 loci through construction of ‘‘credible sets’’ of variants driving eGFR association signals. Credible variants at
the 20 eGFR loci were enriched for DNase I hypersensitivity sites (DHSs) in human kidney cells. DHS credible variants were expression
quantitative trait loci for NFATC1 and RGS14 (at the SLC34A1 locus) in multiple tissues. Loss-of-function mutations in ancestral ortho-
logs of both genes in Drosophila melanogaster were associated with altered sensitivity to salt stress. Renal mRNA expression of Nfatc1 and
Rgs14 in a salt-sensitive mouse model was also reduced after exposure to a high-salt diet or induced CKD. Our study (1) demonstrates the
utility of trans-ethnic fine mapping through integration of GWASs involving diverse populations with genomic annotation from rele-
vant tissues to define molecular mechanisms by which association signals exert their effect and (2) suggests that salt sensitivity might be
an important marker for biological processes that affect kidney function and CKD in humans.Introduction
Chronic kidney disease (CKD) is a major public health
burden and affects nearly 10% of the global population.1
Reduced estimated glomerular filtration rate (eGFR), amea-
sure of kidney function used to define CKD, is associated
with premature cardiovascular disease and mortality, acute
kidney injury, and progression to end stage renal disease
(ESRD).2 Although individuals of African and Hispanic
descent suffer the largest burden of CKD,3 the largest
genome-wide association studies (GWASs) to search for
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are characterized by common variant association signals
that map to large genomic intervals, which contain
many possible causal genes for eGFR, thereby limiting un-
derstanding of the downstream pathogenesis of CKD.
To address this challenge, we have undertaken a trans-
ethnic meta-analysis of nine GWASs comprising 71,638
individuals from four ancestries (African American, His-
panic, European, and East Asian), each imputed up to
the phase 1 integrated (March 2012 release) multi-
ethnic reference panel from the 1000 Genomes Project9,
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Network (COGENT)-Kidney consortium. With these data,
we aimed to (1) assess the evidence for heterogeneity in
allelic effects on eGFR for lead SNPs at kidney-function
loci across ethnic groups; (2) fine-map these loci by taking
advantage of high-density imputation and by leveraging
differences in the pattern of linkage disequilibrium (LD) be-
tween diverse populations to localize ‘‘credible sets’’ of var-
iants driving eGFR association signals; (3) define potential
molecular mechanisms through which eGFR association
signals at these loci impact kidney function through over-
lap of credible variants with genomic annotation; and (4)
assess possible markers for biological processes that impact
kidney function and CKD in humans through targeted
experimentation in model organisms.Subjects and Methods
Ethics Statement
All human research was approved by the relevant institutional
review boards and conducted according to the Declaration of Hel-
sinki. All participants provided written informed consent.
Study Overview
We aggregated five GWASs of individuals of European ancestry
(23,553 individuals from Europe, the USA, and Australia), two
GWASs of Hispanic Americans (16,325 individuals from the
USA), one GWAS of individuals of East Asian ancestry (23,536
individuals from Japan), and one GWAS of African Americans
(8,224 individuals from the USA). Study sample characteristics
are presented in Table S1.
Genotyping, Quality Control, and Imputation
Samples were genotyped with a variety of GWAS arrays, and qual-
ity control was undertaken within each study (Table S2). Sample
quality control included exclusions on the basis of genome-wide
call rate, extreme heterozygosity, sex discordance, cryptic related-
ness, and outlying ethnicity. SNP quality control included exclu-
sions on the basis of call rate across samples and extreme deviation
from Hardy-Weinberg equilibrium. Non-autosomal SNPs were
excluded from imputation and association analysis.
Within each study, the autosomal GWAS genotype scaffold
was first pre-phased10,11 with genetic maps from the International
HapMapConsortium12 tomodel recombination rates. The scaffold
was then imputedup to thephase1 integrated (March2012 release)
multi-ethnic reference panel from the 1000 Genomes Project9
via IMPUTE211,13 or MaCH/Minimac11 (Table S2). Imputed vari-
ants were retained for downstream association analyses if they
attained established GWAS quality control thresholds:14 IMPUTE2
infoR 0.4 or MaCH/Minimac r2R 0.3.
Calculation of eGFR and Association Analysis
Within each study, eGFR was calculated from serum creatinine
(mg/dL), with adjustment for age, sex, and ethnicity by means
of the four-variable MDRD (modification of diet in renal disease)
equation15 to be comparable with published GWASs of kidney
function.4–8 Within each study, we tested association of eGFR
with each variant passing quality control in a linear regression
framework under an additive dosage model and with adjustment
for study-specific covariates to account for confounding due toThe Americanpopulation structure (Table S2). Association summary statistics
were subsequently corrected in each study for residual population
structure through a first round of genomic control16 where neces-
sary (Table S2).
Trans-ethnic Meta-analysis
Association summary statistics were combined across studies via
fixed-effects meta-analysis (inverse-variance weighting) imple-
mented in the GWAMA software.17 Variants passing quality con-
trol in fewer than 50% of the total sample size across studies
were excluded from the meta-analysis. Association summary sta-
tistics from the meta-analysis were then corrected for a second
round of genomic control16 (lGC¼ 1.028). Heterogeneity in allelic
effects between studies at each variant was assessed by means of
Cochran’s Q statistic.18 We extracted association summary statis-
tics for eGFR from the trans-ethnic meta-analysis for previously
reported lead SNPs at established GWAS loci.
LD Calculations
LD, as measured by the correlation coefficient r2, was calculated
on the basis of haplotypes in each ancestry group from the 1000
Genomes Project9 via LDlink.19
Conditional Analyses
To assess the evidence for distinct association signals at each locus
attaining nominal significance (pCOND < 10
5, Bonferroni correc-
tion for ~5,000 variants per locus) in our trans-ethnic meta-anal-
ysis, we performed conditional analysis in a 1Mb genomic interval
flanking the lead SNP. Within each study, we tested association of
eGFR with each variant passing quality control in the flanking re-
gion in a linear regression framework under an additive dosage
model and with adjustment for genotypes at the lead SNP, in addi-
tion to other study-specific covariates used in unconditional anal-
ysis (Table S2). Association summary statistics were subsequently
corrected in each study for residual population structure, via the
same genomic control16 correction employed for unconditional
analysis (Table S2). These association summary statistics were
combined across studies via fixed-effects meta-analysis (inverse-
variance weighting) implemented in GWAMA.17 Variants passing
quality control in less than 50% of the total sample size across
studies were excluded from the meta-analysis. Association sum-
mary statistics from the conditional meta-analysis were then
corrected for a second round of genomic control,16 making use
of the same adjustment as defined in the unconditional analysis
(lGC ¼ 1.028).
Association with CKD
We defined CKD by an eGFR < 60 mL/min/1.73 m2 (calculated
with the MDRD equation defined above) and/or incidence of
ESRD, if available. Any individual who was prospectively initiated
on dialysis or received a kidney transplant (self-reported or ob-
tained from medical records or registries) was defined as having
ESRD. Individuals who did not develop ESRD at follow-up were
considered control subjects. We considered the lead eGFR SNP
identified at each locus attaining genome-wide significance in
our trans-ethnic meta-analysis. Within each study, we tested asso-
ciation of CKD with each SNP in a logistic regression framework
under an additive dosage model and with adjustment for study-
specific covariates to account for confounding due to population
structure (Table S2). Association summary statistics were com-
bined across studies via fixed-effects meta-analysis (sample sizeJournal of Human Genetics 99, 636–646, September 1, 2016 637
and inverse-variance weighting) implemented in METAL20 and
GWAMA.17
Association with eGFR in Diabetic Individuals from
the SUMMIT Consortium
We considered the lead eGFR SNP at each locus attaining genome-
wide significance in our trans-ethnic meta-analysis. We performed
a look-up of association summary statistics for eGFR in 13,158 sub-
jects with diabetes (9,197 with type 2 diabetes [T2D] and 3,961
with type 1 diabetes [T1D]) from five studies of individuals of
European ancestry from the SUMMIT Consortium. Within each
study, the outcome variable was defined as the last measured
eGFR, calculated with the MDRD equation (defined above). Each
study was imputed up to the phase 1 integrated (March 2012
release) multi-ethnic reference panel from the 1000 Genomes
Project.9 Estimated allelic effects on eGFR were obtained from a
linear mixed model and implemented in EMMAX21 with an
empirical genetic relationship matrix, assuming an additive
dosage of the minor allele and including sex, age at diabetes onset,
and duration of diabetes as covariates. Association summary statis-
tics for eGFR were combined across studies via fixed-effects meta-
analysis (inverse-variance weighting) implemented in GWAMA.17
Combined allelic effect estimates across studies were reported for
T1D and T2D subjects, both separately and for all diabetic individ-
uals combined. Heterogeneity in allelic effects between T1D and
T2D subjects at each variant was assessed by means of Cochran’s
Q statistic,18 as implemented in GWAMA.17
For lead SNPs, we tested for a difference in the allelic effect on
eGFR in the general population (from our trans-ethnic meta-anal-
ysis) and in diabetic indivuduals (combined T1D and T2D from
the SUMMIT Consortium) by using a two-sample Z-test.
MANTRA Fine Mapping and Credible Set
Construction
We performed trans-ethnic fine mapping of each locus in a 1 Mb
genomic interval flanking the lead SNP. Association summary sta-
tistics for each variant in the flanking regionwere combined across
studies with a Bayesian hybrid of fixed- and random-effects meta-
analysis, as implemented in MANTRA.22 MANTRA allows for
heterogeneity in allelic effects between ancestry groups arising as
a result of differences in the structure of LD between diverse pop-
ulations by assigning studies to clusters according to a Bayesian
partition model of relatedness between them, defined by pairwise
genome-wide mean allele frequency differences (Figure S1).
MANTRA has been demonstrated, both empirically and by simula-
tion, to improve fine-mapping resolution, as compared to either a
fixed- or random-effects meta-analysis.22–24 Variants passing qual-
ity control in less than 50% of the total sample size across studies
were excluded from the fine-mapping analysis.
We calculated the posterior probability that the jth variant, pCj,
is driving the association signal at each locus by
pCj ¼ LjP
kLk
;
where the summation is over all variants in the flanking interval.
In this expression, Lj is the MANTRA Bayes factor in favor of
association from the trans-ethnic meta-analysis. For each distinct
association signal, a 99% credible set25 was then constructed by (1)
ranking all variants according to their Bayes factor, Lj, and (2)
including ranked variants until their cumulative posterior proba-
bility exceeds 0.99.638 The American Journal of Human Genetics 99, 636–646, SeptembGenomic Annotation
For each locus attaining genome-wide significance in our trans-
ethnic meta-analysis, we obtained genomic annotations of all sin-
gle-nucleotide variants in a 1 Mb interval flanking the lead SNP.
We utilized the Ensembl Variant Effect Predictor (VEP, version
2.7), based on the Ensembl transcript set (version 69). By default,
the VEP reports all possible annotations (transcript- and gene-spe-
cific) for each variant. We therefore prioritized annotations by
considering the most severe consequence of all those reported.
We then calculated the total posterior probability of driving asso-
ciation signals for each consequence across loci.Regulatory Annotation
We collected genomic annotations from three sources. First, we ob-
tained regulatory chromatin states from the Epigenome Roadmap
Project26 for 93 cell types after removing five cancer cell lines. For
each cell type, we pooled enhancer (EnhA and EnhWk) and pro-
moter (TssA and TssFlnk) elements into one annotation. Second,
we obtained 145 non-redundant DNase I hypersensitivity sites
(DHSs) from the ENCODE Project27 by retaining only one dataset
for cell types with multiple assayed samples. Third, we obtained
chromatin immuno-precipitationsequence (ChIP-seq)bindingsites
for 165 transcription factors: 161 proteins from the ENCODE Proj-
ect27 and additional factors assayed in primary pancreatic islets.28
This resulted in a total of 403 annotations for downstream enrich-
ment analyses. For each annotation, we considered variants passing
quality control andmapping within 1Mb of the lead SNP attaining
genome-wide significance in the trans-ethnic meta-analysis.
We first tested the effect of each annotation on the log odds of
the posterior probability of driving eGFR association signals in a
logistic regression model. For each variant, we encoded overlap
with the tested annotation as a binary indicator (1 if variant over-
laps annotation, 0 otherwise). The regression model also incorpo-
rated binary indicators of genic annotations as covariates, as well
as a categorical variable for locus membership. Specifically,
logit

pCj
 ¼ aiLij þ bkxjk þ g30UTRxj30UTR þ g50UTRxj50UTR þ gEXONxjEXON
þ gTSSxjTSS;
where pCj is the posterior probability that the j
th variant drives the
eGFR association; ai denotes an intercept for the i
th locus and Lij is
a binary indicator of membership of the jth variant in the ith locus;
bkdenotes theeffectof the k
th annotationandxkj is abinary indicator
of overlap of the jth variant with the kth annotation; and g30 UTR,
g50 UTR, gEXON and gTSS denote the effects of 3
0 UTRs, 50 UTRs, coding
exons, and the regionwithin 1 kb upstreamofGENCODE transcrip-
tion start site (TSS) annotations, respectively, and xj30 UTR, xj50 UTR,
xjEXON and xjTSS are binary indicators of overlap of the j
th variant
with these annotations. The SE of the effect of the kth annotation,
bk, was evaluated with a robust sandwich variance estimator.
Using fGWAS software, we then tested for the effect of each
annotation by using the Bayes factor in favor of association.29
We included coding exons, 30 UTRs, 50 UTRs, and the region
within 1 kb upstream of the TSS in the model for each annotation.
We obtained the estimated effect and 95% confidence interval (CI)
from this model and considered an annotation enriched if the
95% CI did not overlap zero.Drosophila melanogaster Salt-Sensitivity Assay
Four y1w1 virgin females were mated with two males each of the
genotypes y1w1/Y, y1w1/Y; locoEY-P283/TM3 Sb or y1w1/Y; locod06164er 1, 2016
in rearing vials on standard cornmeal/yeast/molasses food (pre-
pared in a central kitchen at University of Texas Southwestern
Medical Center). The y1w1 isogenic control, in which all loci
had been previously homozygosed, and to which loco mutants
had been backcrossed for six generations, were obtained from
Dr. Yongkyu Park (Rutgers New Jersey Medical School).30 Sepa-
rately, to obtain highly heterozygous progeny (heterogenic), vir-
gin females from the A.R.R. lab’s wBerlin strain were mated with
males of genotypes y1w1/Y, y1w1/Y; locoEY-P283/TM3 Sb or y1w1/Y;
locod06164, as above. Adults were cleared from rearing vials on
rearing day eight. Ten female progeny from each vial were
collected within 1–3 days of eclosion and placed on food
containing various concentrations of added NaCl. Each experi-
mental vial contained flies from a single rearing vial. The number
of dead flies in each vial was counted daily. Flies were transferred
to fresh medium after day five, and again after day ten for the
heterogenic flies. For each concentration of experimental me-
dium, 225 g Applied Scientific Jazz-Mix Drosophila Food (Fisher,
cat. no. AS-153) was added to 500 mL deionized water with con-
stant stirring. Flasks were then placed on a hot plate at 350C
with constant stirring and heated to a slow boil (about 20–
25 min). The heat was then turned off, 4M NaCl was added
to achieve varying concentrations of added NaCl, and total
volume adjusted to 900 mL with deinonized water. Medium
was dispensed in 3–4 mL aliquots in polystyrene vials. All crosses
and assays were performed at room temperature (~22C–23C)
and ambient humidity.
We estimated the effect of the mutations on salt sensitivity by
applying a Cox proportional hazards model on the fly survival
data. The outcome was survival time, and at the end of the
follow-up period, all living flies were censored. The data for each
genetic background (heterogenic or isogenic) and NaCl concentra-
tion were analyzed separately. We estimated the effect on the haz-
ard ratio of genotype (each mutation versus control as baseline).
To account for intra-vial correlation, we used robust sandwich
variance estimators in a generalized estimating equation (GEE)-
like model that treats members of each vial as associated with a
single cluster. Analyses were performed with the R ‘‘survival’’
package.Mouse Renal Expression Study
129S6 mice were purchased from Taconic Biosciences and were
maintained on a 12 hr light-dark cycle with free access to standard
chow and water in the animal facility of the University of Virginia.
Only male mice at 12 weeks of age were used. High-salt diet (HSD,
6%NaCl) in pellets was purchased fromHarlan Teklad and admin-
istered in place of normal chow for two weeks. Experiments were
carried out in accordance with local and NIH guidelines. To induce
CKD, mice were subjected to sub-total nephrectomy (Nx) under
1.5% isoflurane anesthesia, the right kidney was removed, and
the upper branch of the two main branches of the left renal artery
were ligated to impede blood supply to the upper half of the kid-
ney as previously reported.31
Renal mRNA was extracted at the end of 2 weeks of HSD, or at
12 weeks after sub-total Nx. Real-time RT-PCR was performed
as previously described32 with the primers listed in Table S3.
Fluorescence detection was accomplished with Sybr Green and
the iCYcler system (Bio-Rad). mRNA expression was normalized
against mRNA expression of the Hprt housekeeping gene, and
the mean at baseline was used as the reference for determination
of relative expression across conditions.The AmericanResults
Identification of Loci Associated with Kidney
Function across Ancestry Groups
We identified 20 loci attaining genome-wide-significant
evidence of association with eGFR (p < 5 3 108) in
trans-ethnic meta-analysis (Table 1, Figure S2). These loci
have been previously reported in ethnic-specific GWASs
of individuals with European and East Asian ancestry4–6,8
(Table S4). They include two loci discovered in a recently
published meta-analysis of European ancestry GWASs:
LRP2 ([MIM: 600073] rs57989581, p ¼ 5.6 3 1010) and
NFATC1 ([MIM: 600489] rs8096658, p ¼ 1.3 3 108). Pre-
viously reported lead SNPs at an additional 21 established
kidney-function loci attained nominal evidence of associa-
tion (p < 0.05) with eGFR, with consistent direction of
effect (Table S4).
As expected, lead SNPs were common across ancestry
groups at all 20 loci, with each displaying modest effects
on eGFR (Table S5). Despite substantial variability in allele
frequencies between ancestry groups, we observed no evi-
dence of trans-ethnic heterogeneity in allelic effects on
eGFR for any lead SNP (Table 1, Table S5). Through condi-
tional analyses (Table S6), we observed no evidence of mul-
tiple distinct signals of association for eGFR at any locus
(pCOND < 10
5, Bonferroni correction for ~5,000 variants
per locus). Taken together, these data are consistent with
a single variant driving association signals in each locus;
each variant is shared across ancestry groups and has
homogeneous effects on eGFR in diverse populations.
However, we recognize that larger multi-ethnic samples
will be required to detect lower frequency, population-spe-
cific distinct association signals of modest effect on kidney
function.Impact of Lead eGFR SNPs on CKD and Kidney
Function in Diabetic Individuals
We assessed the impact on CKD of lead SNPs at the 20
eGFR loci in a subset of individuals (up to 3,976 cases
and 55,904 controls) contributing to our trans-ethnic
meta-analysis (Table S7). We defined CKD by eGFR <
60 mL/min/1.73 m2 and/or incidence of ESRD. For all 20
lead SNPs, the eGFR-decreasing allele was associated with
increased risk of CKD. Eleven of the lead SNPs demon-
strated evidence of association with CKD at nominal sig-
nificance (p < 0.05), and the strongest signals were
observed at UNCX (rs62435145, p ¼ 2.2 3 107), ALMS1
([MIM: 606844] rs7587577, p ¼ 3.1 3 106), and PDILT-
UMOD ([MIM: 191845] rs77924615, p ¼ 4.0 3 106).
We also investigated the impact of the lead SNPs on
eGFR in GWASs of individuals with diabetes for whom
there are different mechanisms for loss of renal function,
such as diabetic nephropathy. We obtained association
summary statistics for eGFR in 13,158 subjects of European
ancestry with diabetes (9,197 with T2D and 3,961 with
T1D) from the SUMMIT Consortium (Table S8). ConsistentJournal of Human Genetics 99, 636–646, September 1, 2016 639
Table 1. Loci Attaining Genome-wide-Significant Evidence of Association (p< 53 108) with eGFR in Trans-ethnic Meta-analysis of 71,638
Individuals
Locus Lead SNP Chr
Position
(bp, b37)
Alleles Trans-ethnic Meta-analysis
Effecta Other Beta SE p Value
Cochran’s Q
p Value N
SLC43A1 rs35716097 5 176,806,636 T C 1.097 0.127 2.3 3 1017 0.13 71,638
SHROOM3 rs5020545 4 77,414,988 T C 0.969 0.119 1.3 3 1015 0.010 71,638
PDILT-UMOD rs77924615 16 20,392,332 G A 1.185 0.147 1.7 3 1015 0.011 71,638
UNCX rs62435145 7 1,286,567 T G 1.092 0.137 4.7 3 1015 0.17 59,865
GCKR rs1260326 2 27,730,940 C T 0.872 0.114 6.1 3 1014 0.069 71,638
BCAS3 rs9895661 17 59,456,589 C T 1.003 0.132 7.9 3 1014 0.19 71,638
SPATA5L1-GATM rs2486288 15 45,712,339 C T 0.883 0.126 4.7 3 1012 0.76 71,638
ALMS1 rs7587577 2 73,832,786 C T 0.948 0.135 5.2 3 1012 0.098 48,102
CPS1 rs715 2 211,543,055 C T 0.876 0.127 1.3 3 1011 0.21 71,638
WDR72 rs1031755 15 53,951,435 A C 0.860 0.127 2.2 3 1011 0.0013 71,638
PIP5K1B rs4744712 9 71,434,707 A C 0.753 0.112 3.3 3 1011 0.91 71,638
PRKAG2 rs10265221 7 151,414,329 C T 0.963 0.146 7.3 3 1011 0.23 71,638
DAB2-C9 chr5: 39,404,526:D 5 39,404,526 D R 0.817 0.126 1.5 3 1010 0.80 48,102
LRP2 rs57989581 2 170,194,459 C A 1.980 0.315 5.6 3 1010 0.16 71,638
SLC22A2 rs316009 6 160,675,764 C T 1.193 0.192 1.0 3 109 0.49 71,638
LOC100132354-VEGFA rs881858 6 43,806,609 A G 0.772 0.127 2.0 3 109 0.0020 71,638
DCDC5-MPPED2 rs963837 11 30,749,090 T C 0.685 0.114 3.7 3 109 0.0034 71,638
NFATC1 rs8096658 18 77,156,537 G C 0.814 0.141 1.3 3 108 0.015 59,865
PHTF2 rs848486 7 77,552,127 G A 0.643 0.113 2.0 3 108 0.83 71,638
TFDP2 rs1511299 3 141,716,072 T C 0.727 0.131 4.4 3 108 0.55 71,638
aEffect allele is eGFR-decreasing allele.with previous reports,8,33 allelic effects on eGFR in diabetic
individuals and our trans-ethnic meta-analysis of individ-
uals from the general population were homogeneous
(Figure S3). There was nominal evidence of association
with eGFR (p < 0.05), with the same direction of effect,
at seven loci, and the strongest signals were observed at
PDILT-UMOD (p ¼ 6.9 3 106), PRKAG2 ([MIM: 602743]
p ¼ 0.00013) and NFATC1 (p ¼ 0.00045).
Fine Mapping of eGFR Loci
We next sought to localize variants driving eGFR associa-
tion signals in each of the 20 loci attaining genome-wide
significance in our trans-ethnic meta-analysis. We utilized
trans-ethnic fine mapping implemented in MANTRA,22
taking advantage of increased sample size and the expecta-
tion that patterns of LD vary between diverse populations.
We derived credible sets of variants25 mapping within
500 kb of the lead SNP at each locus that together account
for 99% of the posterior probability (pC) of driving the as-
sociation signal (Table S9). Smaller credible sets, in terms of
the number of SNPs they contain, or the genomic interval
that they cover, thus correspond to more precise fine-
mapping. The 99% credible set at the PDILT-UMOD locus640 The American Journal of Human Genetics 99, 636–646, Septembincluded a single variant (rs77924615, pC>0.999), which
maps to an intron of PDILT. This variant has previously
been reported as driving the primary association signal
for CKD at the PDILT-UMOD locus through whole-genome
sequencing and long-range haplotype imputation into
194,286 Icelandic individuals with serum creatinine mea-
surements.34We also observed precise localization, defined
by a 99% credible set including no more than five variants
(Table S10), at a five additional loci: NFATC1 (two variants,
mapping to 0.4 kb), SLC34A1 ([MIM: 182309] two vari-
ants, mapping to 0.6 kb), GCKR ([MIM: 600842] three
variants, mapping to 11.7 kb), DCDC5-MPPED2 ([MIM:
612321, 600911] four variants, mapping to 27.9 kb), and
PIP5K1B ([MIM: 602745] five variants, mapping to 3.5 kb).
Integration of Genetic Fine-mapping and Genomic
Annotation
To gain insight into the mechanisms through which asso-
ciation signals at the 20 GWAS loci attaining genome-wide
significance in our trans-ethnic meta-analysis impact
eGFR, we began by obtaining genomic annotations for
all single-nucleotide variants mapping within 500 kb of
lead SNPs. Across all 20 loci, only 5.4% of the posteriorer 1, 2016
Figure 1. DNase I Hypersensitivity Sites in Kidney Cells and
HDAC8 Binding Sites are Predictive of Posterior Probability of
Driving Association Signals at 20 eGFR Loci
We tested whether genomic annotations of regulatory chromatin
state for 93 cell types, DNase I hypersensitivity sites (DHSs) for 145
cell types, and chromatin immuno-precipitation sequence bind-
ing sites for 165 transcription factors were predictive of posterior
probability of driving eGFR association signals. Each point corre-
sponds to an annotation, plotted according to the effect size
(log-odds ratio for driving association signal) on the x axis and
ranked according to the significance of the association on the
y axis. Significant association (p < 0.00012, highlighted in red)
was defined by Bonferroni correction for 403 tested annotations.
Themost significant effects includedDHSs in kidney cells (RPTECs
and HRCEs) and binding sites for HDAC8.probability of driving association signals was annotated
to coding variants (Table S11), the majority of which was
accounted for by GCKR p.Pro446Leu (rs1260326, pC ¼
0.938). This missense variant has been shown, function-
ally, to result in increased de novo triglyceride and choles-
terol synthesis and export and decreased plasma glucose
concentrations, all of which have been associated with
risk of CKD,35,36 makingGCKR the likely effector transcript
for eGFR at this locus. However, outside of the GCKR locus,
variants mapping to non-coding sequence accounted for
more than 99.4% of the probability of driving eGFR associ-
ation, suggesting that these signals are most likely to be
mediated by effects on gene regulation.
We next investigated whether genomic annotations of
regulatory chromatin state for 93 cell types,26 DHSs for
145 cell types,27 and ChIP-seq binding sites for 165 tran-
scription factors27,28 were predictive of posterior probabil-
ity of driving association signals across the 20 loci (Figure 1,
Table S12). We observed significant effects (p < 0.00012,
Bonferroni correction for 403 annotations) on posterior
probability for variants in kidney DHSs, including
adult renal proximal tubular epithelial cells (RPTECs; p ¼
3.4 3 108), renal cortical epithelial cells (HRCEs; p ¼
4.7 3107), and fetal kidney cells (p ¼ 8.8 3 106). WeThe Americanalso observed significant effects on posterior probability
for transcription-factor binding sites, most notably for
HDAC8 (p ¼ 1.1 3 1014). Histone deacetylases (HDACs)
are involved in kidney function and development,37 and
HDAC inhibitors could be promising in the treatment of
kidney disease.38 We repeated our analyses by using
fGWAS29 (Figure S4, Table S12) and observed strong corre-
lation in the ranking of enriched annotations (r2 ¼ 0.93).
These results highlight that variants driving association
signals with eGFR are more likely to be co-localized with
annotated elements in kidney cells, thereby suggesting
that gene regulation in disease-relevant tissues is a likely
mechanism by which GWAS loci impact CKD.
Lead SNPs that, by themselves, accounted for more than
80% of the posterior probability of driving association
signals overlapped an enriched annotation at five loci (Ta-
ble S13). In particular, at the SLC34A1 locus, rs35716097
(pC ¼ 0.946) overlapped DHSs in RPTECs and HRCEs, as
well as a binding site for HDAC8, while at the NFATC1
locus, rs8096658 (pC ¼ 0.877) overlapped fetal kidney
cell DHSs (Figure S5). At both of these loci, the lead SNPs
were also expression quantitative trait loci (eQTLs) for
NFATC1 and RGS14 (MIM: 602513; at the SLC34A1 locus)
in multiple tissues (Table S13), highlighting these genes as
likely effector transcripts through which eGFR association
signals are mediated. NFATC1 plays a central role in induc-
ible gene transcription during immune response and is a
downstream target of the transplant immunosuppression
drug cyclosporine A. RGS14 encodes a member of the regu-
lator of G protein signaling family, which modulates
downstream effects of Ga subunits and has unknown func-
tion in kidneys.
Experimental Data in Model Organisms
To provide insight into the role of NFATC1 and RGS14 (at
the SLC34A1 locus) in kidney physiology, we examined
the function of ancestral orthologs in Drosophila mela-
nogaster. The Drosophila genome encodes a single member
of the NFAT family, and a previous report has demon-
strated that flies with NFAT loss-of-function mutations
have increased salt sensitivity, suggesting a role for this
gene in ionic or osmotic regulation.39 The closest RGS14
ortholog in Drosophila melanogaster is loco, for which
reduced expression is associated with longer lifespan and
stress resistance.30 We thus conducted experiments aimed
at characterizing a role for loco loss-of-function variants
in salt sensitivity. We compared survival of two inde-
pendently derived heterozygous loco mutants (y1w1;
locod06164/þ and y1w1; locoEY-P283/þ) with isogenic y1w1
controls after supplementing their diet with varying
NaCl concentrations for 8 days (Figure 2). There was very
little mortality of any of the genotypes on non-NaCl-
supplemented food, indicating no baseline differences
in viability over the time period tested. However, we
observed significantly improved survival of the heterozy-
gous loco mutants over controls on NaCl-supplemented
food (Figure 2, Table S14), thereby indicating a roleJournal of Human Genetics 99, 636–646, September 1, 2016 641
Figure 2. Drosophila RGS14 Heterozygous Mutants Are Resistant to Salt Stress
Survival of flies carrying heterozygous loss-of-function mutations in the Drosophila melanogaster RGS14 homolog, loco, was compared to
that of controls of the same genetic background. In the isogenic experiment, all genotypes were backcrossed to the control strain. In the
heterogenic experiment, controls and locomutants were crossed with the A.R.R. lab’s wBerlin strain to obtain highly heterozygous prog-
eny. Kaplan-Meier plots demonstrated that flies heterozygous for two independently derived loco mutations, locoEY-P283 and locod06164,
were resistant to salt stress across a range of NaCl concentrations when compared to controls. Cox-proportional hazards p values for each
mutant, compared to those of controls, are presented and are calculated for each genetic background (isogenic or heterogenic) and NaCl
concentration separately. Results are based on 170–200 flies per genotype for each NaCl concentration.for this gene in resistance to salt stress. To exclude the ef-
fects of inbreeding depression on our findings, we also
repeated our experiments with the same strains on a het-
erogenic background. As expected, the hybrid heterogenic
strains were less salt susceptible than the isogenic strains,
but the loco mutants remained salt-resistant when
compared to controls of a similar genetic background
(Figure 2, Table S14).
To further investigate the role of NFATC1 and RGS14 in
kidney function, we used the 129S6 mouse strain that is
salt-sensitive31 and susceptible to glomerulosclerosis.40
We compared the renal mRNA expression of Nfatc1 and
Rgs14 at baseline versus (1) after a 2-week exposure to
high-salt diet and (2) at 12 weeks after CKD induced by
sub-total nephrectomy. Compared to baseline condition,
Rgs14 was significantly decreased (~75%, p ¼ 0.01) during
high-salt exposure (Figure 3). In the CKD model, Rgs14
expression was also reduced and approached statistical sig-
nificance (p ¼ 0.06). The renal mRNA expression of Nfatc1
was also significantly decreased (~50%, p ¼ 0.03) during
high-salt exposure and trended down in CKD (p ¼ 0.31).
Although we cannot establish cause and effect, these
data illustrate that the expression of both genes is altered
during disease states.642 The American Journal of Human Genetics 99, 636–646, SeptembDiscussion
Wehaveundertaken a trans-ethnicmeta-analysis ofGWASs
of eGFR, supplemented by imputation up to the phase 1 in-
tegrated (March 2012 release) multi-ethnic reference panel
from the 1000 Genomes Project.9 With these high-density
imputed data, we identified 20 loci at genome-wide signifi-
cance for eGFR through trans-ethnicmeta-analysis. Despite
improved coverage of low-frequency variation offered by
high-density imputation, lead SNPs were common across
ancestry groups at all 20 of these kidney-function loci.
There was also minimal evidence of trans-ethnic heteroge-
neity in allelic effects on eGFR at lead SNPs at kidney-func-
tion loci, thereby arguing against the ‘‘synthetic associa-
tion’’ hypothesis.41 It is highly unlikely that eGFR
association signals at these kidney-function loci reflect un-
observed lower frequency causal alleles with larger effects
because (1) rare variants are unlikely to have arisen before
human population migration out of Africa and thus are
not anticipated to be widely shared across diverse popula-
tions9,42 and (2) LD with these variants is expected to be
highly variable between ethnicities.
Our conditional analyses did not provide evidence for
multiple distinct eGFR association signals, which iser 1, 2016
Figure 3. Relative Renal mRNA Expression of Rgs14 and Nfatc1
Expression of Rgs14 is shown in (A) and Nfatc1 in (B). n ¼ 5 or 6 in
each group. The empty triangle represents the median. According
to the Mann-Whitney test, and compared to the baseline, Rgs14
expression after exposure to a high-salt diet was significantly lower
(p¼ 0.01), and was also lower in CKD (p¼ 0.06).Nfatc1 expression
after exposure to a high-salt diet was also significantly lower
(p ¼ 0.03) and trended in the same direction in CKD (p ¼ 0.31).consistent with a single causal variant at each of the 20
eGFR loci. However, we recognize that conditional ana-
lyses evaluate the evidence for residual association at the
locus that cannot be ascribed to the lead SNP and do not
provide a formal framework to test for the presence of mul-
tiple causal variants, for example, that are in strong LD
with each other and reside on the same haplotype. Further-
more, larger sample sizes will be required to detect distinct
association signals defined by common variants of modest
effect or low-frequency variants that might be specific to
particular ethnic groups.
As with most previous GWASs of kidney function, our
study was limited to a single measure of eGFR for each
participant. We also did not adjust for diabetes or hyper-
tension in our analyses given that these conditions
are potential mediators or modifiers of the SNP-eGFR asso-
ciations. However, despite ethnic differences in the preva-
lence of these conditions, we observed no evidence of het-The Americanerogeneity in allelic effects on eGFR between ancestry
groups. Exploration of context-dependent effects should
be considered in future studies, for example, by using
gene-environment interaction or mediation analyses.
Given our observation that eGFR association signals are
shared across ancestry groups, we next sought to take
advantage of the differential patterns of LD across diverse
populations to fine-map kidney-function loci. Credible-
set variants mapped predominantly to non-coding
sequence, suggesting that eGFR association signals are
most likely to be mediated by effects on gene regulation,
in agreement with previous reports for other complex hu-
man traits.43–45 Through integration of genetic fine-map-
ping data with information from regulatory annotation
resources, we have demonstrated significant enrichment
of variants driving eGFR association signals with DHSs in
multiple kidney cell types. Overlap with these enriched an-
notations could be used as a prior model for eGFR associa-
tion signals, genome-wide, to improve power for discovery
of additional kidney-function loci and further enhance
trans-ethnic fine-mapping efforts.46
Lead SNPs at kidney-function loci overlapping enriched
annotations included eQTL for NFATC1 and RGS14 (at
the SLC34A1 locus) in multiple tissues, pointing to likely
effector transcripts through which these eGFR association
signals are mediated. We have established that loss-of-
function mutations in ancestral orthologs of both genes
in Drosophila melanogaster are associated with response to
salt stress. Although salt sensitivity has not been directly
correlated with variation in eGFR in humans, it has been
associated with albuminuria,47,48 elevated creatinine,48
and the subsequent development of hypertension,49 sug-
gesting the relevance of this trait to kidney function.
Indeed, in animal models, salt sensitivity is tightly linked
with a blunted tubuloglomerular feedback (TGF) or
impaired increase in GFR after salt loading.50–53 Consistent
with this, we demonstrated that renal mRNA expression of
Nfatc1 and Rgs14 in a salt-sensitive mouse model was
reduced after exposure to a high-salt diet and induced
CKD. In parallel with the findings in Drosophila mela-
nogaster, these results are consistent with the hypothesis
that the capacity to reduce expression of Rgs14 and Nfatc1
determines the extent of the response to stress. Another
possible mechanism suggested by our results in Drosophila
is a role for oxidative stress, to which RGS14 ortholog
mutants are resistant,30 and which has been implicated
in mammalian salt sensitivity.54,55 Establishing the func-
tional role of these genes in salt sensitivity, TGF, GFR,
oxidative stress, and CKD will require targeted in vivo
studies using knockout and/or transgenic mouse models.
In conclusion, our study demonstrates the utility of
trans-ethnic fine mapping through integration of GWASs
of diverse populations with genomic annotation from
relevant tissues to define molecular mechanisms by which
association signals exert their effect, thereby offering an
exciting opportunity to elucidate the pathophysiology of
complex human diseases.Journal of Human Genetics 99, 636–646, September 1, 2016 643
Supplemental Data
Supplemental Data include five figures, fourteen tables, and Sup-
plemental Acknowledgments and can be found with this article
online at http://dx.doi.org/10.1016/j.ajhg.2016.07.012.Acknowledgments
A.R.R. and J.N.S. are supported by the US NIH (K08DK091316).
T.H.L. is supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (1R01DK094907-01). S.P. is sup-
ported by the US NIH (R25DK101401). G.W.M. is supported by
the Australian National Health and Medical Research Council
Fellowship Scheme. Yukinori Okada was supported by the Japan
Society for the Promotion of Science KAKENHI (15H05911,
15H05670, 15K14429), the Japan Science and Technology Agency,
Mochida Memorial Foundation for Medical and Pharmaceutical
Research, Takeda Science Foundation, Gout Research Foundation,
the Tokyo Biochemical Research Foundation, and the Japan Rheu-
matism Foundation. A.P.M. is a Wellcome Trust Senior Fellow in
Basic Biomedical Science (grant WT098017). N.F. is supported by
the US NIH (5R21HL123677-02). The ESRD data reported here
have been supplied by the United States Renal Data System. The
interpretation and reporting of these data are the responsibility
of the authors and in no way should be seen as official policy or
interpretation of the US government. Additional acknowledg-
ments are provided in the Supplemental Data.
Received: February 17, 2016
Accepted: July 8, 2016
Published: September 1, 2016Web Resources
1000 Genomes, http://www.1000genomes.org
ENCODE, https://www.encodeproject.org/
Ensembl Genome Browser, http://www.ensembl.org/index.html
EPACTS, http://genome.sph.umich.edu/wiki/EPACTS
fGWAS, https://github.com/joepickrell/fgwas
Gencode, http://www.gencodegenes.org
GWAMA, http://www.geenivaramu.ee/en/tools/gwama
IMPUTE2, http://mathgen.stats.ox.ac.uk/impute/impute_v2.html
International HapMap Project, http://hapmap.ncbi.nlm.nih.gov/
LDlink, http://analysistools.nci.nih.gov/LDlink/
METAL, http://www.sph.umich.edu/csg/abecasis/metal/
Minimac, http://genome.sph.umich.edu/wiki/Minimac
OMIM, http://www.omim.org/
Roadmap, http://www.roadmapepigenomics.org/
Variant Effect Predictor, http://useast.ensembl.org/Homo_sapiens/
Tools/VEPReferences
1. Levey, A.S., and Coresh, J. (2012). Chronic kidney disease.
Lancet 379, 165–180.
2. Collins, A.J., Foley, R.N., Gilbertson, D.T., and Chen, S.-C.
(2015). United States Renal Data System public health surveil-
lance of chronic kidney disease and end-stage renal disease.
Kidney Int Suppl (2011) 5, 2–7.
3. Xue, J.L., Eggers, P.W., Agodoa, L.Y., Foley, R.N., and Collins,
A.J. (2007). Longitudinal study of racial and ethnic differences644 The American Journal of Human Genetics 99, 636–646, Septembin developing end-stage renal disease among aged medicare
beneficiaries. J. Am. Soc. Nephrol. 18, 1299–1306.
4. Ko¨ttgen, A., Pattaro, C., Bo¨ger, C.A., Fuchsberger, C., Olden,
M., Glazer, N.L., Parsa, A., Gao, X., Yang, Q., Smith, A.V.,
et al. (2010). New loci associated with kidney function and
chronic kidney disease. Nat. Genet. 42, 376–384.
5. Pattaro, C., Ko¨ttgen, A., Teumer, A., Garnaas, M., Bo¨ger, C.A.,
Fuchsberger, C., Olden, M., Chen, M.-H., Tin, A., Taliun, D.,
et al.; CARDIoGRAM Consortium; ICBP Consortium; CARe
Consortium; Wellcome Trust Case Control Consortium 2
(WTCCC2) (2012). Genome-wide association and functional
follow-up reveals new loci for kidney function. PLoS Genet.
8, e1002584.
6. Okada, Y., Sim, X., Go, M.J., Wu, J.Y., Gu, D., Takeuchi, F.,
Takahashi, A., Maeda, S., Tsunoda, T., Chen, P., et al.;
KidneyGen Consortium; CKDGen Consortium; GUGC con-
sortium (2012). Meta-analysis identifies multiple loci associ-
ated with kidney function-related traits in east Asian popula-
tions. Nat. Genet. 44, 904–909.
7. Gorski, M., Tin, A., Garnaas, M., McMahon, G.M., Chu, A.Y.,
Tayo, B.O., Pattaro, C., Teumer, A., Chasman, D.I., Chalmers,
J., et al. (2015). Genome-wide association study of kidney
function decline in individuals of European descent. Kidney
Int. 87, 1017–1029.
8. Pattaro, C., Teumer, A., Gorski,M., Chu, A.Y., Li, M.,Mijatovic,
V., Garnaas, M., Tin, A., Sorice, R., Li, Y., et al.; ICBP Con-
sortium; AGEN Consortium; CARDIOGRAM; CHARGe-Heart
Failure Group; ECHOGen Consortium (2016). Genetic associ-
ations at 53 loci highlight cell types and biological pathways
relevant for kidney function. Nat. Commun. 7, 10023.
9. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo,M.A., Durbin,
R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and McVean,
G.A.; The 1000 Genomes Project Consortium (2012). An inte-
grated map of genetic variation from 1,092 human genomes.
Nature 491, 56–65.
10. Delaneau, O., Marchini, J., and Zagury, J.F. (2011). A linear
complexity phasing method for thousands of genomes. Nat.
Methods 9, 179–181.
11. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J., and
Abecasis, G.R. (2012). Fast and accurate genotype imputation
in genome-wide association studies through pre-phasing. Nat.
Genet. 44, 955–959.
12. Frazer, K.A., Ballinger, D.G., Cox, D.R., Hinds, D.A., Stuve,
L.L., Gibbs, R.A., Belmont, J.W., Boudreau, A., Hardenbol, P.,
Leal, S.M., et al.; International HapMap Consortium (2007).
A second generation human haplotype map of over 3.1
million SNPs. Nature 449, 851–861.
13. Howie, B.N., Donnelly, P., and Marchini, J. (2009). A flexible
and accurate genotype imputationmethod for the next gener-
ation of genome-wide association studies. PLoS Genet. 5,
e1000529.
14. Winkler, T.W., Day, F.R., Croteau-Chonka, D.C., Wood, A.R.,
Locke, A.E., Ma¨gi, R., Ferreira, T., Fall, T., Graff, M., Justice,
A.E., et al.; Genetic Investigation of Anthropometric
Traits (GIANT) Consortium (2014). Quality control and
conduct of genome-wide association meta-analyses. Nat. Pro-
toc. 9, 1192–1212.
15. National Kidney Foundation (2002). K/DOQI clinical practice
guidelines for chronic kidney disease: evaluation, classification,
and stratification. Am. J. Kidney Dis. 39 (2 Suppl 1), S1–S266.
16. Devlin, B., and Roeder, K. (1999). Genomic control for associ-
ation studies. Biometrics 55, 997–1004.er 1, 2016
17. Ma¨gi, R., and Morris, A.P. (2010). GWAMA: software for
genome-wide association meta-analysis. BMC Bioinformatics
11, 288.
18. Ioannidis, J.P.A., Patsopoulos, N.A., and Evangelou, E. (2007).
Heterogeneity in meta-analyses of genome-wide association
investigations. PLoS ONE 2, e841.
19. Machiela, M.J., and Chanock, S.J. (2015). LDlink: a web-based
application for exploring population-specific haplotype struc-
ture and linking correlated alleles of possible functional vari-
ants. Bioinformatics 31, 3555–3557.
20. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast
and efficient meta-analysis of genomewide association scans.
Bioinformatics 26, 2190–2191.
21. Kang, H.M., Sul, J.H., Service, S.K., Zaitlen, N.A., Kong, S.Y.,
Freimer, N.B., Sabatti, C., and Eskin, E. (2010). Variance
component model to account for sample structure in
genome-wide association studies. Nat. Genet. 42, 348–354.
22. Morris, A.P. (2011). Transethnic meta-analysis of genomewide
association studies. Genet. Epidemiol. 35, 809–822.
23. Franceschini, N., van Rooij, F.J.A., Prins, B.P., Feitosa, M.F.,
Karakas, M., Eckfeldt, J.H., Folsom, A.R., Kopp, J., Vaez, A.,
Andrews, J.S., et al.; LifeLines Cohort Study (2012). Discovery
and fine mapping of serum protein loci through transethnic
meta-analysis. Am. J. Hum. Genet. 91, 744–753.
24. Wang, X., Chua, H.X., Chen, P., Ong, R.T., Sim, X., Zhang, W.,
Takeuchi, F., Liu, X., Khor, C.C., Tay, W.T., et al. (2013).
Comparing methods for performing trans-ethnic meta-anal-
ysis of genome-wide association studies. Hum. Mol. Genet.
22, 2303–2311.
25. Maller, J.B., McVean, G., Byrnes, J., Vukcevic, D., Palin, K., Su,
Z., Howson, J.M., Auton, A., Myers, S., Morris, A., et al.; Well-
come Trust Case Control Consortium (2012). Bayesian refine-
ment of association signals for 14 loci in 3 common diseases.
Nat. Genet. 44, 1294–1301.
26. Bernstein, B.E., Stamatoyannopoulos, J.A., Costello, J.F., Ren,
B.,Milosavljevic, A.,Meissner, A., Kellis, M., Marra, M.A., Beau-
det, A.L., Ecker, J.R., et al. (2010). TheNIHRoadmap Epigenom-
ics Mapping Consortium. Nat. Biotechnol. 28, 1045–1048.
27. ENCODE Project Consortium (2012). An integrated encyclo-
pedia of DNA elements in the human genome. Nature 489,
57–74.
28. Pasquali, L., Gaulton, K.J., Rodrı´guez-Seguı´, S.A., Mularoni, L.,
Miguel-Escalada, I., Akerman, I., Tena, J.J., Mora´n, I., Go´mez-
Marı´n, C., van de Bunt, M., et al. (2014). Pancreatic islet
enhancer clusters enriched in type 2 diabetes risk-associated
variants. Nat. Genet. 46, 136–143.
29. Pickrell, J.K. (2014). Joint analysis of functional genomic data
and genome-wide association studies of 18 human traits. Am.
J. Hum. Genet. 94, 559–573.
30. Lin, Y.R., Kim, K., Yang, Y., Ivessa, A., Sadoshima, J., and Park,
Y. (2011). Regulation of longevity by regulator of G-protein
signaling protein, Loco. Aging Cell 10, 438–447.
31. Cechova, S., Zeng, Q., Billaud, M., Mutchler, S., Rudy, C.K.,
Straub, A.C., Chi, L., Chan, F.R., Hu, J., Griffiths, R., et al.
(2013). Loss of collectrin, an angiotensin-converting enzyme
2 homolog, uncouples endothelial nitric oxide synthase and
causes hypertension and vascular dysfunction. Circulation
128, 1770–1780.
32. Yang, Y., Parsons, K.K., Chi, L., Malakauskas, S.M., and Le, T.H.
(2009). Glutathione S-transferase-micro1 regulates vascular
smooth muscle cell proliferation, migration, and oxidative
stress. Hypertension 54, 1360–1368.The American33. Deshmukh, H.A., Palmer, C.N., Morris, A.D., and Colhoun,
H.M. (2013). Investigation of known estimated glomerular
filtration rate loci in patients with type 2 diabetes. Diabet.
Med. 30, 1230–1235.
34. Sveinbjornsson, G., Mikaelsdottir, E., Palsson, R., Indridason,
O.S., Holm, H., Jonasdottir, A., Helgason, A., Sigurdsson, S.,
Jonasdottir, A., Sigurdsson, A., et al. (2014). Rare mutations
associating with serum creatinine and chronic kidney disease.
Hum. Mol. Genet. 23, 6935–6943.
35. Succurro, E., Arturi, F., Lugara`, M., Grembiale, A., Fiorentino,
T.V., Caruso, V., Andreozzi, F., Sciacqua, A., Hribal, M.L.,
Perticone, F., and Sesti, G. (2010). One-hour postload plasma
glucose levels are associated with kidney dysfunction. Clin.
J. Am. Soc. Nephrol. 5, 1922–1927.
36. Reiss, A.B., Voloshyna, I., De Leon, J., Miyawaki, N., and Mat-
tana, J. (2015). Cholesterol Metabolism in CKD. Am. J. Kidney
Dis. 66, 1071–1082.
37. Chen, S., Bellew, C., Yao, X., Stefkova, J., Dipp, S., Saifudeen,
Z., Bachvarov, D., and El-Dahr, S.S. (2011). Histone deacety-
lase (HDAC) activity is critical for embryonic kidney gene
expression, growth, and differentiation. J. Biol. Chem. 286,
32775–32789.
38. Brilli, L.L., Swanhart, L.M., de Caestecker, M.P., and Hukriede,
N.A. (2013). HDAC inhibitors in kidney development and
disease. Pediatr. Nephrol. 28, 1909–1921.
39. Keyser, P., Borge-Renberg, K., and Hultmark, D. (2007). The
Drosophila NFAT homolog is involved in salt stress tolerance.
Insect Biochem. Mol. Biol. 37, 356–362.
40. Salzler, H.R., Griffiths, R., Ruiz, P., Chi, L., Frey, C.,
Marchuk, D.A., Rockman, H.A., and Le, T.H. (2007). Hyper-
tension and albuminuria in chronic kidney disease mapped
to a mouse chromosome 11 locus. Kidney Int. 72, 1226–
1232.
41. Dickson, S.P., Wang, K., Krantz, I., Hakonarson, H., and Gold-
stein, D.B. (2010). Rare variants create synthetic genome-wide
associations. PLoS Biol. 8, e1000294.
42. Abecasis, G.R., Altshuler, D., Auton, A., Brooks, L.D., Durbin,
R.M., Gibbs, R.A., Hurles, M.E., and McVean, G.A.; The 1000
Genomes Project Consortium (2010). A map of human
genome variation from population scale sequencing. Nature
467, 1061–1073.
43. Trynka, G., Sandor, C., Han, B., Xu, H., Stranger, B.E., Liu, X.S.,
and Raychaudhuri, S. (2013). Chromatin marks identify
critical cell types for fine mapping complex trait variants.
Nat. Genet. 45, 124–130.
44. Parker, S.C., Stitzel, M.L., Taylor, D.L., Orozco, J.M., Erdos,
M.R., Akiyama, J.A., van Bueren, K.L., Chines, P.S., Narisu,
N., Black, B.L., et al.; NISC Comparative Sequencing Program;
National Institutes of Health Intramural Sequencing Center
Comparative Sequencing Program Authors; NISC Compara-
tive Sequencing Program Authors (2013). Chromatin stretch
enhancer states drive cell-specific gene regulation and harbor
human disease risk variants. Proc. Natl. Acad. Sci. USA 110,
17921–17926.
45. Gusev, A., Lee, S.H., Trynka, G., Finucane, H., Vilhja´lmsson,
B.J., Xu, H., Zang, C., Ripke, S., Bulik-Sullivan, B., Stahl, E.,
et al.; Schizophrenia Working Group of the Psychiatric
Genomics Consortium; SWE-SCZ Consortium; Schizophrenia
Working Group of the Psychiatric Genomics Consortium;
SWE-SCZ Consortium (2014). Partitioning heritability of
regulatory and cell-type-specific variants across 11 common
diseases. Am. J. Hum. Genet. 95, 535–552.Journal of Human Genetics 99, 636–646, September 1, 2016 645
46. Kichaev, G., and Pasaniuc, B. (2015). Leveraging functional-
annotation data in trans-ethnic fine-mapping studies. Am. J.
Hum. Genet. 97, 260–271.
47. Bigazzi, R., Bianchi, S., Baldari, D., Sgherri, G., Baldari, G., and
Campese, V.M. (1994). Microalbuminuria in salt-sensitive
patients. A marker for renal and cardiovascular risk factors.
Hypertension 23, 195–199.
48. Bihorac, A., Tezcan, H., Ozener, C., Oktay, A., and Akoglu, E.
(2000). Association between salt sensitivity and target organ
damage in essential hypertension. Am. J. Hypertens. 13,
864–872.
49. Barba, G., Galletti, F., Cappuccio, F.P., Siani, A., Venezia, A.,
Versiero, M., Della Valle, E., Sorrentino, P., Tarantino, G., Fari-
naro, E., and Strazzullo, P. (2007). Incidence of hypertension in
individuals with different blood pressure salt-sensitivity: re-
sults of a 15-year follow-up study. J. Hypertens. 25, 1465–1471.
50. Thurau, K., and Schnermann, J. (1965). The sodium concen-
tration in the macula densa cells as a regulating factor for
glomerular filtration (micropuncture experiments). Klin. Wo-
chenschr. 43, 410–413.646 The American Journal of Human Genetics 99, 636–646, Septemb51. Wilcox, C.S., andWelch, W.J. (1996). TGF and nitric oxide: ef-
fects of salt intake and salt-sensitive hypertension. Kidney Int.
Suppl. 55, S9–S13.
52. Persson, A.E.G., Lai, E.Y., Gao, X., Carlstro¨m, M., and Pat-
zak, A. (2013). Interactions between adenosine, angiotensin
II and nitric oxide on the afferent arteriole influence
sensitivity of the tubuloglomerular feedback. Front. Physiol.
4, 187.
53. Lu, Y., Wei, J., Stec, D.E., Roman, R.J., Ge, Y., Cheng, L., Liu,
E.Y., Zhang, J., Hansen, P.B., Fan, F., et al. (2016). Macula
Densa Nitric Oxide Synthase 1b Protects against Salt-Sensitive
Hypertension. J. Am. Soc. Nephrol. 27, 2346–2356.
54. Kanbay, M., Chen, Y., Solak, Y., and Sanders, P.W. (2011).
Mechanisms and consequences of salt sensitivity and dietary
salt intake. Curr. Opin. Nephrol. Hypertens. 20, 37–43.
55. Morris, R.C., Jr., Schmidlin, O., Sebastian, A., Tanaka, M., and
Kurtz, T.W. (2016). Vasodysfunction that involves renal vaso-
dysfunction, not abnormally increased renal retention of so-
dium, accounts for the initiation of salt-induced hyperten-
sion. Circulation 133, 881–893.er 1, 2016
